Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4044 - IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC


08 Oct 2016


Poster Display


Julien Mazieres


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


J. Mazieres1, F. Barlesi2, O. Molinier3, I. Monnet4, C. Audigier-Valette5, B. Besse6, A. Toffart7, P.A. Renault8, S. Hiret9, S. Fraboulet-Moreau10, B. Mennecier11, P. Masson12, V. Westeel13, P. Souquet14, E. Pichon15, E. Amour16, F. Morin16, D. Moro-Sibilot17

Author affiliations

  • 1 Thoracic Oncology, CHU Toulouse, Hôpital de Larrey, 31059 - Toulouse/FR
  • 2 Assistance Publique Hôpitaux De Marseille, Aix-Marseille University - Faculté de Médecine Nord, 13915 - Marseille/FR
  • 3 Pneumology, Centre Hospitalier Du Mans, Le Mans/FR
  • 4 Pneumologie, CHI de Créteil,, 94010 - Créteil/FR
  • 5 Pneumologie, CHITS Ste Musse (Toulon), Toulon/FR
  • 6 Departement Of Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 7 Pneumologie, CHU Grenoble - Hopital Michallon, Grenoble/FR
  • 8 Pneumologie, Centre hospitalier, Pau/FR
  • 9 Pneumologie, ICO Institut de Cancerologie de l'Ouest René Gauducheau, St. Herblain/FR
  • 10 Pneumologie, Hopital Foch, Suresnes/FR
  • 11 Pneumologie, C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg/FR
  • 12 Pneumologie, CH Cholet, Cholet/FR
  • 13 Pneumologie, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
  • 14 Thoracic Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 15 Service De Pneumologie, CHRU de Tours, Tours/FR
  • 16 Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), Paris/FR
  • 17 Thoracic Oncology, CHU Grenoble - Hopital Michallon, 38043 - La Tronche/FR


Abstract 4044


The incidence of lung cancer is increasing dramatically in women and displays some specific epidemiological, radiological, clinical and pathological characteristics. Two main mechanisms emerged from recent findings in the field of lung carcinogenesis in women: the preferential involvement of the EGFR pathway and the potential impact of hormonal factors. The interaction of estrogen receptors with growth factor receptor signalling has also been shown. Preclinical data have shown that the combination of an EGFR-Tyrosine Kinase Inhibitor (TKI) with an anti-estrogen could overcome resistance to EGFR-TKI by postponing the reactivation of the PI3K-AKT pathway through the estrogen-mediated non-genomic pathway.

Trial design

We launched an open-label phase II randomized trial dedicated to women with advanced stage adenocarcinoma. Patients are treated by gefitinib (250 mg/d) vs. gefitinib + fulvestrant 500 mg MI / month (with a supplementary dose at day 15) in the EGFR mutated group (EGFR +) in first or second line setting and by erlotinib (150 mg/d, according to marketing authorization at trial initiation) vs. erlotinib + fulvestrant in the EGFR wild-type group (EGFR WT) in second or third line setting. Treatments are given until progression or unacceptable toxicity. Follow-up is performed in both arms every month to minimize the potential bias due to monthly fulvestrant injection. Primary objective is progression-free survival (PFS) at 3 and 9 months for EGFR WT and EGFR + patients, respectively. Secondary objectives are safety, overall survival and quality of life. Exploratory objective is biomarkers analysis. The main inclusion criteria are histologically-confirmed non-squamous NSCLC, available tumor tissue for EGFR mutation analysis, post-menopausal women, PS 0-2. The study has been approved by all ethical committees. An ancillary study is ongoing in the EGFR mutated cohort to detect and monitor the EGFR T790M mutation in the serum. First patients have been enrolled in May 2012. To date, 326 patients (162 EGFR + , 164 EGFR WT) have been enrolled and 394 (204 EGFR +, 190 EGFR WT) are expected.

Clinical trial identification


Legal entity responsible for the study



AstraZeneca, Ligue Nationale Contre le Cancer


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings